CEFA-DRI DIN 02173255
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: CEPHAPIRIN (CEPHAPIRIN BENZATHINE)
Health Canada record
| Active ingredient(s) | CEPHAPIRIN (CEPHAPIRIN BENZATHINE) 300 MG |
|---|---|
| Dosage form | Suspension |
| Route | Intramammary |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 13-Nov-2001 |
| Current status date | 08-Sep-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEPHAPIRIN (CEPHAPIRIN BENZATHINE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00845019 | CEFA-DRI INTRAMAMMARY INFUSION 30MG/ML | AYERST LABORATORIES | Suspension | CEPHAPIRIN (CEPHAPIRIN BENZATHINE) 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36390 | 2025-11-18 | Supplement to a New Drug Submission (SNDS) | Change in the manufacturing process for the drug substance, upgrades for sterility assurance |
| 31579 | 2023-09-08 | Supplement to a New Drug Submission (SNDS) | Change in the specification for the drug product tests and replacement of the primary container closure system. |
| 26075 | 2021-06-15 | New Drug Submission (NDS) | Administrative - Change in Product Ownership |
| 24028 | 2020-08-13 | Supplement to a New Drug Submission (SNDS) | Manufacturing change |
| 11516 | 2010-06-16 | New Drug Submission (NDS) | Change in ownership |
| 10253 | 2009-06-16 | Supplement to a New Drug Submission (SNDS) | Alternate source of active ingredient |
| 3487 | 2003-06-27 | New Drug Submission (NDS) | |
| 7027 | 1995-11-03 | New Drug Submission (NDS) |